CAS NO: | 141206-42-0 |
生物活性 | Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor ofglucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2]. | ||||||||||||||||
体外研究 (In Vitro) | Fabry patient-derived fibroblasts with the genotypes R301G (residual -GalA activity; 20%) R220X (<3%) and W162X (<1%). Cell Viability Assay[2].
| ||||||||||||||||
体内研究 (In Vivo) | Lucerastat (1200 mg/kg/day food admix), a GCS inhibitor, reduces Gb3 in the absence of residual ?-GalA activity[2].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 219.28 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C10H21NO4 | ||||||||||||||||
CAS 号 | 141206-42-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 24 mg/mL(109.45 mM;ultrasonic and warming and heat to 80℃) DMSO : 22 mg/mL(100.33 mM;ultrasonic and warming and heat to 80℃) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |